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Neurodegenerative disorders and cancer are severe diseases threatening human health.
The glaring differences between neurons and cancer cells mask the processes involved in
their pathogenesis. Defects in cell cycle, DNA repair, and cell differentiation can determine
unlimited proliferation in cancer, or conversely, compromise neuronal plasticity, leading
to cell death and neurodegeneration. Alteration in regulatory networks affecting gene
expression contribute to human diseases onset, including neurodegenerative disorders,
and deregulation of non-coding RNAs – particularly microRNAs (miRNAs) – is supposed to
have a signiﬁcant impact. Recently, competitive endogenous RNAs (ceRNAs) – acting as
sponges – have been identiﬁed in cancer, indicating a new and intricate regulatory network.
Given that neurodegenerative disorders and cancer share altered genes and pathways, and
considering the emerging role ofmiRNAs in neurogenesis, we hypothesize ceRNAsmay be
implicated in neurodegenerative diseases. Here we propose, and computationally predict,
such regulatory mechanism may be shared between the diseases. It is predictable that
similar regulation occurs in other complex diseases, and further investigation is needed.
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INTRODUCTION
Neurodegenerative diseases (NDs) are assuming a growing rele-
vance in the pathological scenario that jeopardizes human health.
Since degenerative processes are closely age-related,NDs incidence
is stalking the increment of life expectancy in all industrialized
countries. These common and complex disorders are mainly char-
acterized by the selective and progressive death of one or more
speciﬁc neuronal populations, and an elevated number of cases is
represented byAlzheimer’s, Parkinson’s, andHuntington’s diseases
(AD,PD,andHD,respectively). Although the increasing interest in
exploring neurodegenerative phenomena and mechanisms has led
to signiﬁcant progresses, deciphering the molecular basis of NDs
is far from complete. The identiﬁcation of causative mutations in
very rare monogenic Mendelian forms of NDs has provided only
clues to interpret their pathological basis. Most of NDs forms rely
on the combination of multiple genetic and environmental fac-
tors, and the onset and severity are inﬂuenced by their complex
interactions (Ertekin-Taner, 2011). Thus, exclusively investigating
risk factors and mutations in genes responsible of NDs monogenic
forms may be reductive.
Regulatory multilayer networks affecting gene expression are
emerging as relevant contributors in the etiology of human
diseases, including NDs. Particularly, a growing number of stud-
ies are showing deregulation of different classes of non-coding
RNAs (ncRNAs) – microRNAs (miRNAs), long intergenic (lin-
cRNAs) and long non-coding RNAs (lncRNAs) – suggesting
they may have a relevant impact on disease onset/progression
(Esteller, 2011). Their involvement in a variety of biological
processes related to neurogenesis and neurodegeneration – such
as synaptic plasticity – has been demonstrated (Qureshi and
Mehler, 2012).
Recently, and rather unexpectedly, NDs are displaying sim-
ilarities at different levels with cancer. Epidemiological studies
suggest an association between NDs’ incidence and a reduced (or
increased) risk of speciﬁc cancers, although conﬂicting results have
been reported (Plun-Favreau et al., 2010). Cancer cells go through
uncontrolled divisions and show unlimited proliferative potential,
whereas neurons degeneration implies progressive loss of synap-
tic structure or function and substantial cell death. At ﬁrst glance
it might seem paradoxical that a plethora of molecules may be
common to both diseases, even though dramatic changes in tran-
scriptional and post-transcriptional regulation similarly occur in
both cancer cells and degenerating neurons. Accordingly, miRNAs
have been reported in both conditions as key regulators, exerting
their inhibiting roles either on common genes involved in can-
cer and neurodegeneration, either on different genes belonging
to common pathways. Moreover, the same pool of miRNAs can
target distinct genes involved in pathways speciﬁc of each disease
(Du and Pertsemlidis, 2011).
Therefore, since carcinogenesis-related processes and neuronal
circuits functionality involve not only common molecules, but
also multiple similar regulatory mechanisms, here we hypothe-
size these complex disorders may also share a recently described
mechanism of gene expression regulation based on miRNAs
unbalance. Indeed, it has been recently demonstrated in cancer
that some transcribed pseudogenes share miRNA responsive ele-
ments (MREs) with their parent genes competing for the same
miRNAs (Poliseno et al., 2010; Karreth et al., 2011; Tay et al., 2011).
LncRNAs have the same ability of acting as miRNAs sponges
(Cesana et al., 2011; Salmena et al., 2011). Since each miRNA is
predicted to regulate up to hundreds of targets, altered expres-
sion of such transcripts – named competitive endogenous RNAs
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(ceRNAs) – may disrupt the equilibrium of available miRNAs, in
turn modifying mRNAs abundance. Given such considerations,
we speculate that ceRNA mechanism, demonstrated in cancer,
may also be involved in NDs etiology.
Therefore, to evaluate the potential impact of ceRNA-mediated
regulation of gene expression in NDs, we independently ana-
lyzed pseudogenes and their parent genes, with evidence of
differential expression in AD, PD, and HD, disclosing predicted
miRNAs binding sites common to pseudogene/gene pairs. Simi-
larly, we identiﬁed a restricted pool of miRNAs targeting lncRNAs
differentially expressed in such diseases. Our analysis suggests
these deregulated non-coding transcripts (both pseudogenes and
lncRNAs) may act as ceRNAs. Thus, we propose a new regu-
latory mechanism – common to neurodegenerative and cancer
processes – may exist, and it cannot be excluded that a simi-
lar regulatory network may also underlie other human complex
diseases.
miRNA FUNCTION
MicroRNAs, endogenously expressed small (20–25 nucleotides)
single-stranded RNAs, play crucial roles in the post-transcrip-
tional regulation, binding a short region (seed) of mRNAs – a
complementary sequence usually located in 3′ UTRs – and con-
sequently leading to transcripts’ degradation (Guo et al., 2010) or
repressing their translation (Bartel, 2009). Since each miRNA can
target thousand of genes and, vice versa, each gene can be targeted
by several miRNAs (Rajewsky and Socci, 2004; Rajewsky, 2006),
such molecules are crucially implied in the ﬁne-tuned regulation
of gene expression. The proven involvement of miRNAs both
in physiological and pathological processes has rapidly exposed
them to the spotlight, shifting the research focus toward this class
of ncRNAs1 (Packer et al., 2008; Patel et al., 2008; Martí et al.,
2010; Margis et al., 2011; Miñones-Moyano et al., 2011; Chan and
Kocerha, 2012; Geekiyanage et al., 2012).
miRNA IN NEURODEGENERATION
Understanding brain functionality has always represented a fas-
cinating and challenging goal. Nonetheless, its complex structure
and inaccessibility havemade extremely difﬁcult to study neurode-
generative processes. The identiﬁcation of causative mutations
explains only a little percentage of ND cases (Sutherland et al.,
2011), whereas the alteration of gene expression levels and
epigenetic changes, are emerging as new contributors to neu-
rodegenerative disorders. Indeed, AD and PD can be seen as
“gene-dosage effect” disorders: AD could be caused by gene
duplication of Aβ precursor protein (APP; Podlisny et al., 1987;
Rovelet-Lecrux et al., 2006), likewise α-synuclein locus duplication
or triplication causes PD (Singleton et al., 2003; Chartier-Harlin
et al., 2004). Thus, it is reasonable to speculate that altered levels of
some crucial transcripts may have a dramatic impact on neurons
functionality.
Speciﬁc patterns of miRNAs expression in restricted areas have
been documented in brain development and senescence (Miska
et al., 2004; Kapsimali et al., 2007). In the past few years, a growing
number of reports have shown that precursor and mature miRNA
1www.mir2disease.org
transcripts and miRNA processing machinery itself (Drosha and
Dicer) are disrupted during ND progression (Hébert et al., 2009;
Ghose et al., 2011; Schoﬁeld et al., 2011). In particular, gene expres-
sion analyses of sporadic PD (Kim et al., 2007) and AD (Lukiw,
2007; Cogswell et al., 2008) revealed that miRNA deregulation is
associated to neurodegeneration, and that some miRNAs repress
APP expression (Long and Lahiri, 2011; Liu et al., 2012), although
discordant results suggest that some experimental and technical
concerns still exist (discussed in Costa et al., 2010, 2012).
Nonetheless, the hypothesis that miRNAs are involved in ND
etiology is intriguing, and understanding how, and at what extent,
they contribute to neurodegenerative processes remains a crucial
endpoint.
ceRNA THEORY
Competition among different classes of RNAs for a pool of
miRNAs has been ﬁrst suggested, then demonstrated, by both
theoretical and experimental studies (Seitz, 2009; Poliseno et al.,
2010; Karreth et al., 2011; Tay et al., 2011). Seitz (2009) proposed
that many computationally identiﬁed miRNA target genes might
represent some “non-legitimate targets,” or low-afﬁnity miRNAs
“pseudotargets.”Therefore, such mRNAs would act as competitive
inhibitors of miRNAs, by preventing their binding to legitimate
targets.
In the wake of such hypothesis, the “competing endogenous
RNAs” theory (Salmena et al., 2011) has proposed the existence
of legitimate bona ﬁde miRNA competitors, such as demonstrated
for the gene/pseudogene pairsPTEN /PTENP1 andKRAS/KRAS1P
(Karreth et al., 2011; Tay et al., 2011). mRNAs can talk each other
through their 3′ UTRs, and the “indirect interactions” can regu-
late their expression levels. Such transcribed – but untranslated –
regions containMREswhich can regulate in cis the transcript levels
itself and in trans can alter the levels of different pools of miRNAs,
consequently affecting the levels of other mRNAs. Such theory,
experimentally conﬁrmed in a mouse model of melanoma (Kar-
reth et al., 2011; Tay et al., 2011), proposes that virtually all types of
RNA can communicate each other through a new fascinating“bio-
logical alphabet,” in which MREs are the “letters” whose different
combinations may form an entire universe of “words” (Licatalosi
et al., 2008; Chi et al., 2009).
PSEUDOGENES IN NEURODEGENERATIVE DISEASES
The contribution of ceRNAs to the availability of miRNAs in
the cell has been established in cancer, and their altered expres-
sion modiﬁes the abundance of mRNAs (Poliseno et al., 2010; Tay
et al., 2011). Thus, understanding the contribution of ceRNAs on
gene expression deregulation is particularly relevant not only in
different tumors but also in other human complex diseases. In
particular, since recent evidences showNDs share common altered
genes, pathological mechanisms, and cellular processes with can-
cer, we decided to address whether ceRNAs may contribute also to
NDs pathogenesis.
Therefore, we ﬁrst identiﬁed the subset of genes differen-
tially expressed in AD, PD, and HD, retrieving datasets from
Gene Expression Atlas database2 (accession n. E-MTAB-62,
2http://www.ebi.ac.uk/gxa/
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FIGURE 1 | (A) Venn diagram showing intersections of DE genes in all three
NDs. Colored circles contain the number of genes per disease. (B) Bar graph
showing the distribution of all the miRNAs binding sites (y-axis) identiﬁed in
lncRNAs DE in HD (x -axis) which bind the same miRNA. Matrixes built with
the lncRNAs and the restricted set of miRNAs (having common binding
sites within lncRNAs sequences), for HD (C) and PD (D). Red and blue
squares indicate the presence and the absence (respectively) of miRNA
binding within the target lncRNA.
E-GEOD-3790, E-GEOD-1751, E-AFMX-6, E-GEOD-7621, E-
GEOD-7307, E-GEOD-20295, E-GEOD-20168, E-MEXP-2280,
E-GEOD-6613). Particularly, only genes with a statistical sig-
niﬁcance of differential expression inferred from at least two
independent experiments were used. As shown in Figure 1A, these
datasets consisted of 17, 1002, and 5361 genes, forAD,PD,andHD,
respectively. Interestingly, by using a bootstrap resampling proce-
dure (105 iterations), a signiﬁcant overlap (563 genes; p  0.01)
was disclosed between genes DE in PD and HD (Figure 1A),
showing they may represent crucial genes in the etiology of neu-
rodegeneration. Moreover, in line with the notion that common
genes with proven involvement in cancer and in NDs are deregu-
lated in both conditions (Morris et al., 2010; Plun-Favreau et al.,
2010; Du and Pertsemlidis, 2011), pathway analysis (performed
using PANTHER; Thomas et al., 2003) revealed a signiﬁcant over-
lap with cancer hallmarks, including apoptosis, p53, Ras, PDGF,
FGF, EGF, and MAPK signaling pathways (data not shown).
Since pseudogenes have been shown to act as miRNAs sponges
in cancer we evaluated such ﬁnding also in NDs. Thus, we
intersected the above-described datasets of DE genes in NDs with
a full list of human pseudogenes retrieved from HUGO Gene
Nomenclature Committee (HGNC) database. The intersection
revealed that 49, 1, and 10 pseudogenes are DE in HD, AD, and
PD, respectively. Thus, 3′ UTR sequences of pseudogenes and
their parent genes were downloaded from University of Califor-
nia Santa Cruz (UCSC) and aligned by using BLAT algorithm to
assess sequence identity. Only pseudogenes’ sequences showing
high homology (95–99%) were used as described below. The 3′
UTRs of some parent genes aligned outside the boundaries of their
annotated cognate pseudogenes, indicated the need to revise anno-
tations. In such cases, we used for further computational analysis
the matching genomic sequences. Therefore, FASTA sequences of
selected pseudogenes and the 3′ UTRs of parent genes were inde-
pendently scanned for the presence of miRNA binding sites using
a TargetScan perl script (Lewis et al., 2005). Pseudogenes with
only one miRNA binding site were excluded from further analy-
ses. Analyzed pseudogene/gene pairs – in each ND – are listed in
Table 1.
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Table 1 | Pseudogenes deregulated in HD, PD andAD sharing
common miRNA binding sites with their parent genes.
Pseudogene/gene pair miRNA family
Pseudogene Gene n common (%)
Huntington’s disease
BCRP2/BCR* 41 71 38 (92.7)
BZW1P2/BZW1* 4 50 4 (100.0)
CES1P1/CES1 6 6 6 (100.0)
CHCHD2P2/CHCHD2 4 5 2 (50.0)
COX7A2P2/COX7A2* 3 5 2 (66.7)
DGKZP1/DGKZ 14 16 14 (100.0)
EEF1A1P5/EEF1A1* 9 64 8 (88.9)
EIF2S2P4/EIF2S2 6 33 6 (100.0)
ETF1P1/ETF1 24 59 19 (79.2)
FABP5P1/FABP5 3 2 2 (66.7)
FAM108A3P/FAM108A1 6 7 6 (100.0)
FAM115B/FAM115A* 76 76 74 (97.4)
GBP1P1/GBP1* 39 33 24 (61.5)
HIGD1AP14/HIGD1A* 19 56 14 (73.7)
HMGA1P4/HMGA1* 2 36 1 (50.0)
HMGB1P1/HMGA1* 42 36 29 (69.0)
HMGB1P10/HMGB1 15 48 13 (86.7)
HMGB1P5/HMGB1 14 48 13 (92.9)
HMGN1P36/HMGN1 11 11 10 (90.9)
HMGN2P3/HMGN2 12 24 12 (100.0)
HNRNPA3P1/HNRNPA3 53 118 5 (9.4)
HSD17B7P2/HSD17B7 7 9 6 (85.7)
HTR7P1/HTR7 35 43 17 (48.6)
MT1P2/MT1G* 2 4 2 (100.0)
MT1P2/MT1H* 2 5 2 (100.0)
NANOGP8/NANOG 18 17 17 (94.4)
NSUN5P1/NSUN5 15 39 12 (80.0)
PI4KAP2/PI4KA 7 7 5 (71.4)
POU5F1P4/POU5F1 7 9 6 (85.7)
PPP1R2P3/PPP1R2* 58 55 38 (65.5)
PTENP1/PTEN* 23 91 21 (91.3)
RBBP4P4/RBBP4 13 147 11 (84.6)
RBMS1P1/RBMS1* 15 52 15 (100.0)
RHOQP2/RHOQ* 52 93 48 (92.3)
RP9P/RP9 16 19 15 (93.8)
RPLP0P6/RPLP0* 2 2 1 (50.0)
S100A11P1/S100A11* 6 5 3 (50.0)
SKP1P1/SKP1* 25 35 18 (72.0)
TLK2P1/TLK2 20 64 19 (95.0)
VDAC1P1/VDAC1* 21 26 20 (95.2)
VEZF1P1/VEZF1* 64 85 53 (82.8)
YWHAZP3/YWHAZ* 11 54 8 (72.7)
ZFAND6P1/ZFAND6 15 16 14 (93.3)
(Continued)
Table 1 | Continued
Pseudogene/gene pair miRNA family
Pseudogene Gene n common (%)
Parkinson’s disease
CHCHD2P2/CHCHD2 4 5 2 (50.0)
HSD17B7P2/HSD17B7 7 9 6 (85.7)
NSUN5P1/NSUN5 15 39 12 (80.0)
NSUN5P2/NSUN5 13 39 11 (84.6)
PHC1P1/PHC1 47 46 46 (87.9)
PPP1R2P3/PPP1R2 58 55 38 (65.5)
RBMXP2/RBMX 26 59 22 (84.6)
Alzheimer’s disease
CRYBB2P1/CRYBB2 6 5 5 (83.3)
*Genes DE in the related disease.
This analysis revealed that pseudogenes deregulated in HD,
AD, and PD, share (on average) about 80% of miRNA binding
sites with their parent genes, suggesting these highly expressed –
but untranslated – transcripts may represent novel ceRNAs, pos-
sibly subtracting a relevant fraction of common miRNAs to the
physiological regulation of their parent genes. Interestingly, our
analysis revealed that two pseudogenes,PTENP1 and POU5F1P4 –
recently described as ceRNAs in cancer (Poliseno et al., 2010) – are
differentially expressed inNDs and share a very signiﬁcant fraction
of MREs (about 90%) with their parent genes (see Table 1).
Our ﬁndings strengthen the hypothesis of a novel convergent
ceRNA-mediated regulatory mechanism, underlying both can-
cerogenesis and neurodegenerative process. We cannot exclude
that over-expression of such pseudogenes may subtract a pool
of miRNAs not only to their parent genes, but they may also
contribute to a more global gene deregulation, accounting for dis-
ease etiology. Systematic analysis of DE pseudogenes in NDs, and
further targeted functional studies are needed to conﬁrm these
observations.
LncRNA IN NEURODEGENERATIVE DISEASES
Long non-coding RNAs are a numerous class of non-protein
coding transcripts longer than 200 nucleotides. Prior studies
and, more recently, transcriptomic analyses by Next Genera-
tion Sequencing (NGS), indicate the lncRNAs are as abundant
as mRNAs (Carninci et al., 2005; Guttman et al., 2009; Cabili et al.,
2011). Given their proven key role in many biological processes
and their restricted expression pattern in speciﬁc brain regions
(Mercer et al., 2008), it is reasonable to speculate they may be
altered in NDs and be involved in their etiology (Johnson, 2012;
Niland et al., 2012). Furthermore, the hypothesis that lncRNAs
could sequester miRNAs and act as ceRNAs (Cesana et al., 2011;
Salmena et al., 2011), suggests a novel fascinating role for them
in NDs.
In light of these considerations, we examined lncRNAs differ-
entially expressed in NDs, similarly to pseudogenes analysis. By
using an in silico approach and a list of human lncRNAs obtained
from HGNC database, we identiﬁed 31, 4, and 1 lncRNAs DE in
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HD, PD, and AD, respectively. Since they are alternatively spliced,
we retrieved the sequences corresponding to all splicing transcripts
(222, 5, and 1 Ensembl transcripts for HD, PD, and AD, respec-
tively) and we scanned them for the presence of miRNA binding
sites. In AD, the only lncRNA signiﬁcantly DE was BACE1-AS
whose role in Alzheimer’s pathogenesis has been already reported
(Faghihi et al., 2008, 2010). Our analysis revealed BACE1-AS has
predicted binding sites for 18 miRNAs, some of with proven asso-
ciation to AD, such as let-7, mir-127, mir-93a (Chan and Kocerha,
2012; Lehmann et al., 2012), suggesting it may be an intriguing
ceRNA candidate inAD etiology. The distribution of MREs within
lncRNAs DE in HD (Figure 1B) and PD was evaluated in order to
identify the lncRNAs sharing a pool of common MREs. By using a
bootstrap resampling procedure we created random sets of lncR-
NAs that underwent the same miRNA analysis. We measured their
MREs distributions observing they signiﬁcantly differ from our
observations (p < 0.05).
Moreover, given the large number of lncRNAs DE in HD and
PD, we used random datasets also to set two thresholds on the
number of lncRNAs sharing common MREs, whose values were
10 for HD and 2 for PD. Such thresholds were used to select – for
further analysis – a restricted pool of miRNAs whose seeds match
at least 10 and 2 lncRNAs analyzed for HD and PD, respectively.
Thus, we built two matrixes (one for disease) with all the lncRNAs
altered in a speciﬁc disease and its related stringent set of miRNAs
(Figures 1C and 1D for HD and PD, respectively).
Although predictive and computationally-based, our analy-
sis shows that lncRNAs deregulated in NDs share a pool of
MREs, suggesting such long untranslated transcripts may rep-
resent a previously undetected source of competitive binding
sites also for brain-speciﬁc miRNAs, thus potentially acting as
ceRNAs.
PERSPECTIVES AND CONCLUSIONS
Growing interest in understanding the basis of neurodegenera-
tive processes has led to signiﬁcant steps forward, even though
many underlying molecular aspects are still unknown. The identi-
ﬁcation of disease-causing mutations in Mendelian forms of NDs
and genome-wide associations studies have only partially provided
satisfactory explanation to disease pathogenesis, whereas gene
expression studies, and the analysis of their regulation, are cur-
rently giving a signiﬁcant contribution to better understand NDs.
Particularly,miRNAs andother ncRNAs are showing relevant roles
in neural cell plasticity as well as in neurodegenerative processes
(Junn and Mouradian, 2012).
In cancer, recent evidences show that untranslated transcripts,
pseudogenes, and presumably lncRNAs, named ceRNAs, com-
pete for a pool of miRNAs acting as endogenous sponges and
regulating parent genes and other mRNAs (Poliseno et al., 2010;
Karreth et al., 2011; Salmena et al., 2011; Tay et al., 2011). Such
ﬁndings are likely to have broader implications for other diseases
and cellular processes, largely beyond the regulationof few genes in
cancer.
Therefore, given that NDs and cancer share common causative
genes and altered signaling molecular pathways, even considering
the crucial role of miRNAs in neurogenesis- and cancerogenesis-
related processes, we have proposed and computationally pre-
dicted both pseudogenes and lncRNAs may be involved in the
etiology of AD, HD, and PD, acting as ceRNAs.
In such NDs, independent analysis of DE lncRNAs, pseudo-
genes, and parent genes, revealed they contain a huge number
of shared MREs, potentially representing miRNAs sponges. It
suggests that ceRNAs may represent the rule, rather than the
exception, also in the etiology of NDs. Our observations indi-
cate that a ceRNA-based regulatory mechanism might be shared
between neurodegenerative and cancerous processes, and we can-
not exclude that similar complex regulatory networks may also
underlie other human complex diseases. However, studying pseu-
dogenes is challenging due to the high sequence identity with their
parent genes, and genome-wide expression studies may report
conﬂicting results about pseudogenes expression. The introduc-
tion of NGS, particularly of RNA sequencing, is substantially
contributing to overcome some technological challenges for the
transcriptome analysis (Cloonan et al., 2008; Mortazavi et al.,
2008; Costa et al., 2010, 2011) also for studying expressed pseudo-
genes.We believe this technologywill increasingly help researchers
to encrypt the novel ceRNAs code, giving an incredible boost to
understand this new “language.”
Finally, targeted functional studies are clearly needed to vali-
date and conﬁrm this predictive study, even though we believe that
ceRNAs have traced a novel revolutionary route in the landscape
of human genetics.
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